WO2025257758 - SOLID STATE FORMS OF NAVACAPRANT

National phase entry is expected:
Publication Number WO/2025/257758
Publication Date 18.12.2025
International Application No. PCT/IB2025/055980
International Filing Date 11.06.2025
Title **
[English] SOLID STATE FORMS OF NAVACAPRANT
[French] FORMES À L'ÉTAT SOLIDE DE NAVACAPRANT
Applicants **
ASSIA CHEMICAL INDUSTRIES LTD.
Inventors
MUTHUSAMY, Anantha Rajmohan
SOMASUNDARAM, Meenakshi Sundaram
KAUSHIK, Babita
Priority Data
202411045161   11.06.2024   IN
202411046810   18.06.2024   IN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2416
EPO Filing, Examination, Granting13355
Japan Filing, Examination, Granting2462
South Korea Filing, Examination, Granting2726
USA Filing, Examination, Granting8740
MasterCard Visa
Total: 29,699
Contact Us
Abstract[English] The present disclosure relates to solid state forms of Navacaprant salts, such as Navacaprant L-tartrate and Navacaprant hydrochloride. In embodiments crystalline polymorphs or salts of Navacaprant, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.[French] La présente divulgation concerne des formes à l'état solide de sels de navacaprant, tels que le L-tartrate de navacaprant et le chlorhydrate de navacaprant. Des modes de réalisation de la présente divulgation concerne des polymorphes cristallins ou des sels de navacaprant, leurs procédés de préparation, des compositions pharmaceutiques de ceux-ci et leurs procédés d'utilisation.